Actively Recruiting
PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
Led by Massachusetts General Hospital · Updated on 2026-04-20
50
Participants Needed
1
Research Sites
13 weeks
Total Duration
On this page
Sponsors
M
Massachusetts General Hospital
Lead Sponsor
U
United States Department of Defense
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating PDAC-PATHWAYS, a digital app designed to provide information and supportive care for patients starting neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC). The study includes two parts: an open pilot to refine the app and a pilot randomized controlled trial (RCT) to test its feasibility and acceptability compared to usual care. The trial focuses on patients with newly diagnosed, non-metastatic PDAC initiating therapy. Participants in the pilot RCT will be randomly assigned to either use the PDAC-PATHWAYS app or receive standard treatment from their oncology clinicians. The app aims to support patients through their treatment journey, while those in the usual care group continue with routine clinical care. The study evaluates enrollment and intervention completion rates as primary outcomes over 10 weeks. During the study, participants will complete baseline surveys and be monitored for their engagement with the app or usual care processes. Researchers will collect data on feasibility, acceptability, and intervention completion to understand how well the app supports patients initiating neoadjuvant therapy. The total participation period includes these assessments over a 10-week timeframe.
CONDITIONS
Brief Title
PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Within 8 weeks of a documented decision to start neoadjuvant therapy for newly diagnosed, non-metastatic pancreatic ductal adenocarcinoma
- Able to understand and speak English
You will not qualify if you...
- Presence of other health conditions that would interfere with study participation as determined by the cancer care team
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 10 weeks
Participants use the PDAC-PATHWAYS digital app or receive usual care while initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Baseline survey and ongoing use of app or routine care
Trial Site Locations
Total: 1 location
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
Research Team
K
Kelsey Lau-Min, MD, MSCE
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here